ClinicalTrials.gg

Program

isatuximab

Also written as “Isatuximab SAR650984”, “Isatuximab” and “isatuximab SAR650984”.

Its studies are mostly in Multiple Myeloma · Lymphoma · Immune System Diseases · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Anemia, Hemolytic, Autoimmune, led by 3 companies.

Furthest: phase 3, since Dec 4, 201623 company-led studies, 6 open or runningNext primary completion: Apr 5, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi215 open or runningphase 3since Dec 4, 2016Mar 9, 2010Apr 5, 2027phase 3 · NCT03319667
GlaxoSmithKline11 open or runningphase 2since Oct 13, 2025Oct 13, 2025none ahead
Hoffmann-La Roche10 open or runningphase 2since May 31, 2018May 31, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Mar 9, 2010.

  1. May 31, 2018Hoffmann-La Roche's first study: phase 2 study in Colorectal NeoplasmsNew to Hoffmann-La RocheHoffmann-La Roche · NCT03555149 · 96 enrolled · United States, Australia, France and more
  2. Aug 5, 2018Phase 2 study in NeoplasmsSanofi · NCT03637764 · 107 enrolled · United States, Belgium, Canada and more
  3. Oct 31, 2018Phase 1 study in Multiple MyelomaSanofi · NCT03733717 · 25 enrolled · China
  4. Nov 29, 2018Phase 2 study in LymphomaSanofi · NCT03769181 · 58 enrolled · France, Italy, Netherlands and more
  5. Feb 21, 2019Phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaSanofi · NCT03860844 · 67 enrolled · United States, Argentina, Brazil and more
  6. Aug 2, 2019Phase 1 study in Multiple MyelomaSanofi · NCT04045795 · 56 enrolled · United States, Australia, Belgium and more
  7. Feb 13, 2020Phase 3 study in Multiple MyelomaSanofi · NCT04270409 · 337 enrolled · United States, Australia, Brazil and more
  8. Feb 19, 2020Phase 2 study in Immune System DiseasesSanofi · NCT04294459 · 23 enrolled · United States, Spain
  9. Dec 1, 2020Phase 2 study in Warm Autoimmune Hemolytic Anemia (wAIHA)Sanofi · NCT04661033 · 8 enrolled · United States, France, Germany and more
  10. May 31, 2022Phase 3 study in Plasma Cell Myeloma RecurrentSanofi · NCT05405166 · 531 enrolled · United States, Argentina, Australia and more
  11. Dec 20, 2022Phase 2 study in Multiple MyelomaSanofi · NCT05669989 · 70 planned · United States, Australia, Brazil and more
  12. Jan 20, 2023Phase 2 study in Multiple MyelomaSanofi · NCT05704049 · 118 enrolled · Australia, Brazil, China and more
  13. Oct 13, 2025GlaxoSmithKline's first study: phase 2 study in Multiple MyelomaNew to GlaxoSmithKlineGlaxoSmithKline · NCT07217184 · 30 enrolled · United States, Australia, Brazil and more
  14. Oct 26, 2026Primary completion moved from 2027-01-08 to 2027-04-01Date moved laterphase 2 · +3 months · NCT06356571

Ahead

  1. Apr 5, 2027Primary completion: phase 3 study in Multiple MyelomaSanofi · NCT03319667
  2. Nov 30, 2028Primary completion: phase 2 study in Multiple MyelomaSanofi · NCT05669989
  3. Oct 14, 2030Primary completion: phase 3 study in Multiple MyelomaSanofi · NCT04270409

TargetBeta

CD38 →read by rule
“A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 ”NCIt, by rule
“Lymphocyte differentiation antigen CD38 inhibitor”ChEMBL 37, by rule

Other programs on CD38

ProgramCompanyFurthest phaseStudies
daratumumabruleJohnson & Johnsonphase 444
felzartamabruleBiogenphase 315
mezagitamabruleTakedaphase 311
lumrotatugruleKeymed Biosciencesphase 310
Anti-CD38 Monoclonal Antibody SCTC21CruleSinocelltech Groupphase 35
sanritatugruleHangzhou Sumgen Biotechphase 35
CID-103ruleCASI Pharmaceuticalsphase 23
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD38 Monoclonal AntibodyruleChongqing Genrix Biopharmaceuticalphase 21
Anti-CD38 Antibody-drug Conjugate ABBV-438AbbViephase 11

Studies

All 23 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07217184Multiple Myeloma · United States, Australia, Brazil and more2Active, not recruitingGlaxoSmithKlineApr 17, 202530
NCT05704049Multiple Myeloma · Australia, Brazil, China and more2Active, not recruitingSanofiDec 22, 2025118
NCT05669989Multiple Myeloma · United States, Australia, Brazil and more2By invitationSanofiNov 30, 202870
NCT05405166Plasma Cell Myeloma Recurrent · United States, Argentina, Australia and more3Active, not recruitingSanofiNov 6, 2024531
NCT04661033Warm Autoimmune Hemolytic Anemia (wAIHA) · United States, France, Germany and more2TerminatedSanofiJun 26, 20238
NCT04294459Immune System Diseases · United States, Spain2TerminatedSanofiMay 2, 202223
NCT04270409Multiple Myeloma · United States, Australia, Brazil and more3Active, not recruitingSanofiOct 14, 2030337
NCT04045795Multiple Myeloma · United States, Australia, Belgium and more1CompletedSanofiMar 27, 202456
NCT03860844Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, Argentina, Brazil and more2TerminatedSanofiSep 12, 202267
NCT03769181Lymphoma · France, Italy, Netherlands and more2TerminatedSanofiNov 8, 202258
NCT03733717Multiple Myeloma · China1CompletedSanofiSep 6, 202025
NCT03637764Neoplasms · United States, Belgium, Canada and more2TerminatedSanofiMay 11, 2022107
NCT03555149Colorectal Neoplasms · United States, Australia, France and more2TerminatedHoffmann-La RocheSep 26, 202296
NCT03367819Prostatic Neoplasms · United States, France, Italy and more2TerminatedSanofiMar 10, 202144
NCT03319667Multiple Myeloma · United States, Australia, Belgium and more3Active, not recruitingSanofiApr 5, 2027475
NCT02999633Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · United States, Finland, France and more2TerminatedSanofiNov 14, 201714
NCT02990338Multiple Myeloma · United States, Australia, Belgium and more3CompletedSanofiNov 22, 2018307
NCT02812706Multiple Myeloma · Japan2CompletedSanofiJul 31, 201836
NCT02514668Multiple Myeloma · United States, Czechia, France1CompletedSanofiDec 2, 202155
NCT02513186Multiple Myeloma · France, Germany, Italy and more1CompletedSanofiJan 28, 202290
NCT02283775Multiple Myeloma · United States1CompletedSanofiMay 26, 202154
NCT01749969Multiple Myeloma · United States1CompletedSanofiJun 20, 202357
NCT01084252Hematologic Neoplasms · United States, Argentina, Belgium and more2CompletedSanofiDec 21, 2018351

How it is read

Names in the registry

  • “Isatuximab SAR650984”, 11 entries
  • “Isatuximab”, 6 entries
  • “isatuximab SAR650984”, 3 entries
  • “Isatuximab intravenous (IV)”, 1 entry
  • “Isatuximab subcutaneous (SC)”, 1 entry

Codes read as this program: SAR650984.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.